The CSL share price is a sleeping dividend giant. Here's why

CSL shares aren't considered serious dividend payers. But this could be a costly mistake.

| More on:
A tired healthcare or lab worker sleeps on her desk

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The ASX is home to many dividend heavyweights
  • But CSL shares aren't usually considered among these
  • Here's why that assumption may be a mistake

 The CSL Limited (ASX: CSL) share price has been a staple of the S&P/ASX 200 Index (ASX: XJO) for decades now. In fact, CSL has spent its time over the past decade or so climbing up from the middle of the ASX 200 pack to the number three position on the Index that it now occupies.

But unlike its fellow top ASX 200 shares, such as BHP Group Ltd (ASX: BHP) or the big four banks, CSL has never been regarded as a dividend heavyweight. 

A quick look at the CSL share price today will probably tell you why. Right now, CSL has a trailing dividend yield of just 1.11%. That only comes partially franked too.

In stark contrast, BHP shares currently offer a fully-franked trailing yield of 8.86% right now. Commonwealth Bank of Australia (ASX: CBA) is at a fully-franked 4.2%, while Westpac Banking Corp (ASX: WBC) offers 5.62%.

So dividend-chasing income investors probably won't take too long in deciding which shares to have in their portfolios. But those investors might want to take a second look because all is not quite as it seems at first glance. 

Yes, you won't get as much dividend income upfront buying CSL shares as you would BHP or one of the big four banks. But CSL could well be a sleeping divided giant and one whose dividends might approach, or even exceed, the level of income offered by ASX's other heavyweights in just a few years.

Here's why.

Why the CSL share price could be a sleeping dividend giant

CSL first started paying its investors dividends back in 2013. The company's very first dividend payment was a final dividend worth 52 US cents per share. In 2014, the company doled out annual dividend payments worth US$1.13 per share.

But just five years later in 2019, CSL was up to paying out US$1.85 in dividends per share. By 2022, this had risen again to a total of US$2.22 per share.

In US dollar terms, CSL has consistently raised its annual dividend every single year since 2013. Because of currency exchange rates, we can't say the same for its dividends in Aussie dollar terms. But the trend is clear.

In 2023 so far, this trend has continued too. The interim dividend that investors received only earlier this month came in at US$1.07 per share. That was a significant hike over 2022's corresponding payment of US$1.04 per share.

Between 2014 and 2022, CSL's annual dividend rocketed by a cumulative 96.5%. If CSL's dividends keep rising at this level over the next eight years, investors will be bagging US$4.36 in dividends per share by the year 2030. That's $6.54 per share in Australian dollars at the current exchange rate.

If that were to occur (which is by no means guaranteed), it would be highly lucrative for long-term investors, and would finally make CSL an ASX dividend heavyweight.

So this just proves that you can't judge an ASX divided share by the yield on its cover. By the time the 'sleeping giant' awakens, it might be too late to nab the shares at a good share price.

 

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended Westpac Banking. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »